Details of the Drug

General Information of Drug (ID: DMMTAJC)

Drug Name

Potassium chloride

Synonyms

Acronitol; Celeka; Chloropotassuril; Chlorvescent; Durekal; Durules; Enpott; Enseal; Infalyte; KCL; KSR; Kadalex; Kalcorid; Kaleorid; Kaleorod; Kaliduron; Kaliglutol; Kalilente; Kalinorm; Kaliolite; Kalipor; Kalipoz; Kalitabs; Kaliumchlorid; Kaochlor; Kaskay; Kato; Kayback; Kayciel; Kaysiel; Keylyte; Kloren; Klorvess; Klotrix; Kolyum; Miopotasio; Neobakasal; Pfiklor; Potasion; Potasol; Potavescent; Rekawan; Selora; Steropotassium; Sylvite; [KCl]; Chlorid draselny; Chlorid draselny [Czech]; Chloride of potash; Conductance standard solution; Dipotassium dichloride; Emplets potassium chloride; K Tab; KCL Retard; KM potassium chloride; Kalinorm Depottab; Kalitrans Retard; Kalium Duriles; Kalium Durules; Kalium Retard; Kalium SR; Kaon Cl; Kaon Ultra; Kay Ciel; Kelp salt; Leo K; Monopotassium chloride; Muriate of potash; Natural sylvite; Plus Kalium Retard; Potassium Chloride BP; Potassium Chloride in Plastic Container; Potassium Cl; Potassium chloride [JAN]; Potassium chloride solution; Potassium chloride standard; Potassium monochloride; Potassium muriate; Rekawan Retard; Repone K; Sal digestnum sylvii; Super K; Tripotassium trichloride; Trona muriate of potash; Trona potassium chloride; Ultra K Chlor; IN2900; Potassium Chloride 10meq in Plastic Container; Potassium chloride 20meq inplastic container; Potassium chloride 30meq in plastic container; Potassium chloride 40meq in plastic container; Addi-K; Apo-K; Cena-K; Chloride, Potassium; Chloropotassuril diffu-K; Diffu-K; Duffi-K; Durules-K; K+10; K+8; K-10; K-Care; K-Contin; K-Dur; K-Grad; K-Lease; K-Lor; K-Lyte Cl; K-Norm; K-SR; K-Sol; K-Tab; K. tab; KCL (TN); KCl-retard Zyma; Kalinor-Retard P; Kalium S.R; Kalium-Durettes; Kalium-R; Kalium-duriles; Kaon Cl-10; Kaon-Cl; Kaon-Cl 10; Kaon-Cl TABS; Kaon-ci; Kay-Ciel; Kay-EM; Klor-Con; Klor-Con M10; Klor-Con M15; Klor-Con M20; Klor-Lyte; Klotrix (TN); Lento-K; Lento-Kalium; Leo-K; Micro-K; Micro-K 10; Micro-K Extentcaps; Micro-K LS; Micro-Kalium Retard; Nu-K; POTASSIUM CHLORIDE, ACS; Peter-kal; Potassium atomic spectroscopy standard concentrate 1.00 g K; Potassium chloride (K3Cl3); Potassium chloride (KCl); Potassium standard concentrate 10.00 g K; Potassium thallium chloride (KTlCl); Repone-K; Rum-K; Sando-K; Slow-K; Slow-K tablets; Span-K; Super K (salt); Ten-K; Clor-K-Zaf; Hydrochloric acid potassium salt (1:1); ISA (ionic strength adjustment solution: 1 M KCl); K-Lyte/Cl; K-Predne-Dome; K-dur (TN); K-lyte/C1; Kalium S.R.; Kaon-Cl (TN); Kay-Cee-L; Klor-con (TN); Potassium chloride (JP15/USP); Ultra-K-Chlor; Conductivity Standard Solution, 1413-S/cm; Conductivity Standard Solution, 500-S/cm; POTASSIUM CHLORIDE, U.S.P.; 11118_FLUKA

Indication

Disease Entry	ICD 11	Status	REF
Hypokalemia	5C77	Approved	[1]

Therapeutic Class

Dietary supplement

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

74.55

Topological Polar Surface Area

Not Available

Rotatable Bond Count

Hydrogen Bond Donor Count

Hydrogen Bond Acceptor Count

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Elimination: 85% of drug is excreted from urine in the unchanged form [2]
Water Solubility: The ability of drug to dissolve in water is measured as 333.3 mg/mL [2]

Chemical Identifiers

Formula: ClK
IUPAC Name: potassium;chloride
Canonical SMILES: [Cl-].[K+]
InChI: InChI=1S/ClH.K/h1H;/q;+1/p-1
InChIKey: WCUXLLCKKVVCTQ-UHFFFAOYSA-M

Cross-matching ID

PubChem CID: 4873
ChEBI ID: CHEBI:32588
CAS Number: 7447-40-7
DrugBank ID: DB00761
TTD ID: D0E9JM
VARIDT ID: DR00184
ACDINA ID: D00543

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Solute carrier family 12 member 1 (SLC12A1)	TTS087L	S12A1_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Electroneutral potassium-chloride cotransporter 3 (SLC12A6)	DTMA4FJ	S12A6_HUMAN	Substrate	[4]
Electroneutral potassium-chloride cotransporter 2 (SLC12A5)	DTD62VB	S12A5_HUMAN	Substrate	[5]
Electroneutral potassium-chloride cotransporter 1 (SLC12A4)	DTY25IU	S12A4_HUMAN	Substrate	[6]
Basolateral Na-K-Cl symporter (SLC12A2)	DTHKL3Q	S12A2_HUMAN	Substrate	[7]
Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2 (SLC12A1)	DTO1UQY	S12A1_HUMAN	Substrate	[8]
Organic cation/carnitine transporter 2 (SLC22A5)	DT3HUVD	S22A5_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Potassium chloride (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Mepyramine	DMB4SFH	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[27]
Phenyltoloxamine	DMKAEQW	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[27]
Desipramine	DMT2FDC	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[28]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of hyperkalemia by the combination of Potassium chloride and Phenylbutazone.	Chronic pain [MG30]	[29]
Ketoprofen	DMRKXPT	Moderate	Increased risk of hyperkalemia by the combination of Potassium chloride and Ketoprofen.	Chronic pain [MG30]	[29]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Potassium chloride and Drospirenone.	Contraceptive management [QA21]	[30]
Cyclobenzaprine	DM1YBRM	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Cyclobenzaprine.	Depression [6A70-6A7Z]	[28]
Clomipramine	DMINRKW	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Clomipramine.	Depression [6A70-6A7Z]	[28]
Doxepin	DMPI98T	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Doxepin.	Depression [6A70-6A7Z]	[27]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of hyperkalemia by the combination of Potassium chloride and Mefenamic acid.	Female pelvic pain [GA34]	[29]
Eprosartan	DM07K2I	Major	Increased risk of hyperkalemia by the combination of Potassium chloride and Eprosartan.	Hypertension [BA00-BA04]	[31]
Aliskiren	DM1BV7W	Moderate	Increased risk of hyperkalemia by the combination of Potassium chloride and Aliskiren.	Hypertension [BA00-BA04]	[32]
Captopril	DM458UM	Major	Increased risk of hyperkalemia by the combination of Potassium chloride and Captopril.	Hypertension [BA00-BA04]	[33]
TAK-491	DMCF6SX	Major	Increased risk of hyperkalemia by the combination of Potassium chloride and TAK-491.	Hypertension [BA00-BA04]	[31]
Perindopril	DMOPZDT	Major	Increased risk of hyperkalemia by the combination of Potassium chloride and Perindopril.	Hypertension [BA00-BA04]	[33]
Quinapril	DMR8H31	Major	Increased risk of hyperkalemia by the combination of Potassium chloride and Quinapril.	Hypertension [BA00-BA04]	[33]
Telmisartan	DMS3GX2	Major	Increased risk of hyperkalemia by the combination of Potassium chloride and Telmisartan.	Hypertension [BA00-BA04]	[31]
Irbesartan	DMTP1DC	Major	Increased risk of hyperkalemia by the combination of Potassium chloride and Irbesartan.	Hypertension [BA00-BA04]	[34]
Tolvaptan	DMIWFRL	Moderate	Increased risk of hyperkalemia by the combination of Potassium chloride and Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[35]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of hyperkalemia by the combination of Potassium chloride and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[36]
Clidinium	DMUMQZ0	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Clidinium.	Irritable bowel syndrome [DD91]	[28]
Dicyclomine	DMZSDGX	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Dicyclomine.	Irritable bowel syndrome [DD91]	[28]
Promethazine	DM6I5GR	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Promethazine.	Nausea/vomiting [MD90]	[28]
Diflunisal	DM7EN8I	Moderate	Increased risk of hyperkalemia by the combination of Potassium chloride and Diflunisal.	Pain [MG30-MG3Z]	[29]
Ibuprofen	DM8VCBE	Moderate	Increased risk of hyperkalemia by the combination of Potassium chloride and Ibuprofen.	Pain [MG30-MG3Z]	[29]
Biperiden	DME78OA	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Biperiden.	Parkinsonism [8A00]	[28]
Orphenadrine	DMW542E	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Orphenadrine.	Parkinsonism [8A00]	[28]
Bromfenac	DMKB79O	Moderate	Increased risk of hyperkalemia by the combination of Potassium chloride and Bromfenac.	Postoperative inflammation [1A00-CA43]	[29]
Meloxicam	DM2AR7L	Moderate	Increased risk of hyperkalemia by the combination of Potassium chloride and Meloxicam.	Rheumatoid arthritis [FA20]	[29]
Oxaprozin	DM9UB0P	Moderate	Increased risk of hyperkalemia by the combination of Potassium chloride and Oxaprozin.	Rheumatoid arthritis [FA20]	[29]
Molindone	DMAH70G	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Molindone.	Schizophrenia [6A20]	[28]
Brompheniramine	DMFOVSD	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[28]
Acrivastine	DMTIGA0	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Potassium chloride and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[28]
-----------


⏷ Show the Full List of 33 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Alpha-tocopherol	E00243	14985	Antimicrobial preservative; Antioxidant
Diethyl phthalate	E00135	6781	Plasticizing agent; Solvent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Oleic acid	E00421	445639	Emulsifying agent; Penetration agent; Solubilizing agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Vanillin	E00049	1183	Flavoring agent
Acetyltributyl citrate	E00127	6505	Plasticizing agent
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Calcium stearate	E00244	15324	lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone	E00626	Not Available	Disintegrant
Dibutyl sebacate	E00160	7986	Plasticizing agent
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 1000	E00647	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 37 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Potassium chloride 10 meq tablet	10 meq	Extended Release Oral Tablet	Oral
Potassium chloride 8 meq tablet	8 meq	Extended Release Oral Tablet	Oral
Potassium chloride 10 meq capsule	10 meq	Extended Release Oral Capsule	Oral
Potassium chloride 20 meq tablet	20 meq	Extended Release Oral Tablet	Oral
Potassium chloride 8 meq capsule	8 meq	Extended Release Oral Capsule	Oral
Potassium chloride 1500 mg tablet	1500 mg	Extended Release Tablet	Oral
Potassium chloride 750 mg tablet	750 mg	Extended Release Tablet	Oral
Potassium chloride 10 meq tablet	10 meq	Extended Release Tablet	Oral
Potassium chloride 20 meq tablet	20 meq	Extended Release Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070999.
2	BDDCS applied to over 900 drugs
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Functional analysis of a potassium-chloride co-transporter 3 (SLC12A6) promoter polymorphism leading to an additional DNA methylation site. Neuropsychopharmacology. 2009 Jan;34(2):458-67.
5	Tyrosine phosphorylation regulates the membrane trafficking of the potassium chloride co-transporter KCC2. Mol Cell Neurosci. 2010 Oct;45(2):173-9.
6	Human potassium chloride cotransporter 1 (SLC12A4) promoter is regulated by AP-2 and contains a functional downstream promoter element. Blood. 2004 Jun 1;103(11):4302-9.
7	Expression of the sodium potassium chloride cotransporter (NKCC1) and sodium chloride cotransporter (NCC) and their effects on rat lens transparency. Mol Vis. 2010 May 4;16:800-12.
8	Rare mutations in renal sodium and potassium transporter genes exhibit impaired transport function. Curr Opin Nephrol Hypertens. 2014 Jan;23(1):1-8.
9	Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch. 2010 Jul;460(2):505-23.
10	Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2010;25(1):112-9.
11	Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84.
12	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
13	Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Drug Metab Dispos. 2017 Dec;45(12):1240-1244.
14	Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8.
15	Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
16	Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Biopharm Drug Dispos. 2009 Dec;30(9):495-507.
17	Cloning and functional characterization of a novel up-regulator, cartregulin, of carnitine transporter, OCTN2. Arch Biochem Biophys. 2006 Aug 1;452(1):29-37.
18	Upregulation of renal sodium transporters in D5 dopamine receptor-deficient mice. Hypertension. 2010 Jun;55(6):1431-7.
19	Nongenomic effect of aldosterone on ion transport pathways of red blood cells. Cell Physiol Biochem. 2008;22(1-4):269-78.
20	Update of diuretics in the treatment of hypertension. Am J Ther. 2007 Mar-Apr;14(2):154-60.
21	Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37.
22	Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74.
23	Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
24	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
25	Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72.
26	The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52.
27	Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8. [PMID: 4013604]
28	Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
29	Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
30	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
31	Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12. [PMID: 6744599]
32	Product Information. Tekturna (aliskiren). Novartis Pharmaceuticals, East Hanover, NJ.
33	Product Information. K-Dur (potassium chloride). Schering Laboratories, Kenilworth, NJ.
34	Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812. [PMID: 14525902]
35	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
36	Product Information. K-Phos Original (potassium acid phosphate). Beach Pharmaceuticals, Tampa, FL.